

**Curcumin Maintenance Therapy for Ulcerative Colitis:
Randomized,
Multicenter, Double-Blind, Placebo-Controlled Trial**

Multicenter, randomized, double-blind, placebo-controlled trial. Patients with quiescent ulcerative colitis were randomized to curcumin 1 gr twice daily + sulfasalazine or mesalazine vs placebo + mesalazine or sulfasalazine.

Primary endpoint: Maintenance of remission up to 6 months.

Results: N=89

- At 6 months relapse occurred in: 4.65% curcumin+5ASA vs 20.51% placebo+5ASA, $p=0.040$

Conclusion:

Curcumin seems to be a promising and safe medication for maintaining remission in patients with quiescent UC.

Relapse at 6 months

